Skip to main content

Table 1 Clinical and laboratory characteristics of 304 patients associated with overall survival (OS)

From: The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma

Patient characteristicsNo. of patients (%)Median OS (IQR)P-valuea
Gender
 Male232 (76.3%)44.2 (38.5–47.4)0.967
 Female72 (23.7%)44.8 (40.7–46.8) 
Age (years)
 ≤46157 (51.6%)45.0 (40.6–47.8)0.202
 > 46147 (48.4%)43.4 (37.2–46.8) 
Tumor stage
 T1–252 (17.1%)46.2 (41.9–49.8)0.043
 T3–4252 (82.9%)44.0 (38.3–46.9) 
Node stage
 N0–1168 (55.3%)44.5 (40.8–47.0)0.007
 N2–3136 (44.7%)43.9 (36.0–47.8) 
TNM stageb
 I–II33 (10.9%)45.8 (41.3–48.0)0.048
 III–IV271 (89.1%)44.2 (39.2–47.1) 
Treatment
 Radiotherapy43 (14.1%)44.0 (40.7–48.1)0.047
 Chemoradiotherapy261 (85.9%)44.4 (38.7–47.0) 
CRP (mg/L)
 ≤ 2.03131 (43.1%)44.6 (41.9–47.4)0.001
 > 2.03173 (56.9%)44.1 (36.0–47.0) 
SAA (mg/L)
 ≤ 4.46154 (50.7%)44.7 (41.7–47.4)0.001
 > 4.46150 (49.3%)43.3 (35.2–47.1) 
PLR
 ≤ 141.52167 (54.9%)44.0 (40.1–47.0)0.287
 > 141.52137 (45.1%)45.1 (37.2–47.5) 
NLR
 ≤ 2.62149 (49.0%)44.2 (40.6–47.5)0.006
 > 2.62155 (51.0%)44.5 (36.1–47.0) 
LMR
 ≤ 1.8729 (9.5%)45.3 (42.1–50.3)0.415
 > 1.87275 (90.5%)44.2 (39.2–47.0) 
EBV DNA (copies/mL)
 ≤ 2340161 (53.0%)45.0 (40.9–47.6)<0.001
 > 2340143 (47.0%)43.4 (36.0–46.4) 
  1. aSurvival was analyzed using Kaplan–Meier method and compared with Log-Rank test;
  2. bTNM stage was classified according to the AJCC 7th TNM staging system;
  3. IQR interquartile range, TNM tumor node metastasis stage, CRP C-reactive protein, SAA serum amyloid A, PLR platelet/lymphocyte ratio, NLR neutrophil/lymphocyte ratio, LMR ymphocyte/monocyte ratio, EBV Epstein-Barr virus